DK3294740T3 - Hidtil ukendte sulfonimidoylpurinonforbindelser og derivater til behandling og profylakse af virusinfektion - Google Patents

Hidtil ukendte sulfonimidoylpurinonforbindelser og derivater til behandling og profylakse af virusinfektion Download PDF

Info

Publication number
DK3294740T3
DK3294740T3 DK16720421T DK16720421T DK3294740T3 DK 3294740 T3 DK3294740 T3 DK 3294740T3 DK 16720421 T DK16720421 T DK 16720421T DK 16720421 T DK16720421 T DK 16720421T DK 3294740 T3 DK3294740 T3 DK 3294740T3
Authority
DK
Denmark
Prior art keywords
prophylaxis
derivatives
novel
treatment
viral infection
Prior art date
Application number
DK16720421T
Other languages
Danish (da)
English (en)
Inventor
Chungen Liang
Kun Miao
Jianping Wang
Hongying Yun
Xiufang Zheng
Original Assignee
H Hoffmann La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55910966&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3294740(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Hoffmann La Roche Ag filed Critical H Hoffmann La Roche Ag
Application granted granted Critical
Publication of DK3294740T3 publication Critical patent/DK3294740T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK16720421T 2015-05-08 2016-05-04 Hidtil ukendte sulfonimidoylpurinonforbindelser og derivater til behandling og profylakse af virusinfektion DK3294740T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2015078507 2015-05-08
CN2016078785 2016-04-08
PCT/EP2016/059961 WO2016180695A1 (en) 2015-05-08 2016-05-04 Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection

Publications (1)

Publication Number Publication Date
DK3294740T3 true DK3294740T3 (da) 2019-11-04

Family

ID=55910966

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16720421T DK3294740T3 (da) 2015-05-08 2016-05-04 Hidtil ukendte sulfonimidoylpurinonforbindelser og derivater til behandling og profylakse af virusinfektion

Country Status (32)

Country Link
US (3) US9708325B2 (enExample)
EP (1) EP3294740B1 (enExample)
JP (1) JP6738352B2 (enExample)
KR (1) KR102690131B1 (enExample)
CN (1) CN107580596B (enExample)
AR (1) AR104528A1 (enExample)
AU (3) AU2016260683B2 (enExample)
BR (1) BR112017023959B1 (enExample)
CA (1) CA2982704C (enExample)
CL (1) CL2017002745A1 (enExample)
CO (1) CO2017009994A2 (enExample)
CR (1) CR20170496A (enExample)
DK (1) DK3294740T3 (enExample)
ES (1) ES2753777T3 (enExample)
HR (1) HRP20191942T1 (enExample)
HU (1) HUE045906T2 (enExample)
IL (2) IL254947B (enExample)
LT (1) LT3294740T (enExample)
MX (2) MX393198B (enExample)
MY (1) MY182353A (enExample)
NZ (2) NZ735648A (enExample)
PE (1) PE20171620A1 (enExample)
PH (1) PH12017502009A1 (enExample)
PL (1) PL3294740T3 (enExample)
PT (1) PT3294740T (enExample)
RS (1) RS59435B1 (enExample)
RU (1) RU2745269C2 (enExample)
SG (1) SG10202108841YA (enExample)
SI (1) SI3294740T1 (enExample)
TW (2) TWI706954B (enExample)
UA (1) UA120450C2 (enExample)
WO (1) WO2016180695A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2982704C (en) * 2015-05-08 2023-10-24 F. Hoffmann-La Roche Ag Sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
PH12019500432B1 (en) * 2016-08-29 2023-03-24 Hoffmann La Roche 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection
MX388408B (es) * 2016-09-13 2025-03-19 Hoffmann La Roche Tratamiento combinado con un agonista de tlr7 y un inhibidor de montaje de capsida de hbv
JP7328977B2 (ja) 2018-02-12 2023-08-17 エフ. ホフマン-ラ ロシュ アーゲー ウイルス感染の処置および予防のための新規のスルホン化合物および誘導体
MA52412A (fr) * 2018-02-28 2021-06-02 Hoffmann La Roche Nouveaux composés sulfonimidoylpurinone substitués en position 7 et dérivés pour le traitement et la prophylaxie du cancer du foie
CN111072667A (zh) * 2018-10-22 2020-04-28 罗欣药业(上海)有限公司 五元或六元杂环并嘧啶类化合物及其用途
CN113660957B (zh) * 2019-02-12 2024-12-13 Ambrx公司 包含抗体-tlr激动剂缀合物的组合物、方法和用途
BR112022005137A2 (pt) 2019-09-20 2022-06-14 Syngenta Crop Protection Ag Derivados heterocíclicos com substituintes contendo enxofre e sulfoximina ativos em termos pesticidas
WO2021154664A1 (en) * 2020-01-27 2021-08-05 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
EP4097103A1 (en) * 2020-01-27 2022-12-07 Bristol-Myers Squibb Company 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists
EP4554678A1 (en) 2022-07-14 2025-05-21 F. Hoffmann-La Roche AG Phosphorylpurinone compounds for the treatment of cancer
CN118724963A (zh) * 2023-03-30 2024-10-01 浙江养生堂天然药物研究所有限公司 含磷或含硫的大环化合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4189048B2 (ja) * 1997-12-26 2008-12-03 大日本住友製薬株式会社 複素環化合物
CN101203519A (zh) * 2005-05-04 2008-06-18 辉瑞有限公司 用于治疗癌症和病毒感染如丙型肝炎的用作Toll样受体调节剂的2-酰氨基-6-氨基-8-氧代嘌呤衍生物
CN101239980B (zh) 2008-02-18 2011-06-22 靳广毅 免疫受体调节剂偶联体前体和偶联体及其应用
CN103497192B (zh) * 2008-12-09 2015-09-23 吉里德科学公司 Toll样受体调节剂
WO2011079016A1 (en) 2009-12-22 2011-06-30 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
TWI555737B (zh) 2011-05-24 2016-11-01 拜耳知識產權公司 含有硫醯亞胺基團之4-芳基-n-苯基-1,3,5-三氮雜苯-2-胺
KR102025276B1 (ko) 2011-11-09 2019-09-25 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염 치료를 위한 퓨린 유도체
AU2014242954B2 (en) 2013-03-29 2018-03-15 Janssen Sciences Ireland Uc Macrocyclic deaza-purinones for the treatment of viral infections
EA032824B1 (ru) 2014-08-15 2019-07-31 Чиа Тай Тяньцин Фармасьютикал Груп Ко., Лтд. Пирролопиримидиновые соединения, используемые в качестве агониста tlr7
CA2982704C (en) * 2015-05-08 2023-10-24 F. Hoffmann-La Roche Ag Sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
PH12019500432B1 (en) * 2016-08-29 2023-03-24 Hoffmann La Roche 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection

Also Published As

Publication number Publication date
AU2016260683A1 (en) 2017-10-12
KR20180003612A (ko) 2018-01-09
AR104528A1 (es) 2017-07-26
RS59435B1 (sr) 2019-11-29
AU2016260683B2 (en) 2020-10-29
CO2017009994A2 (es) 2018-02-20
PE20171620A1 (es) 2017-11-02
SI3294740T1 (sl) 2019-12-31
US20170275286A1 (en) 2017-09-28
CR20170496A (es) 2017-12-05
IL280769A (en) 2021-04-29
MX376761B (es) 2025-03-07
TWI706954B (zh) 2020-10-11
EP3294740B1 (en) 2019-09-04
CL2017002745A1 (es) 2018-05-18
MX2020010949A (es) 2022-06-16
MY182353A (en) 2021-01-20
RU2017142577A (ru) 2019-06-10
PL3294740T3 (pl) 2020-03-31
MX393198B (es) 2025-03-19
JP6738352B2 (ja) 2020-08-12
EP3294740A1 (en) 2018-03-21
AU2020256348A1 (en) 2020-11-12
US20200109144A1 (en) 2020-04-09
AU2022204666A1 (en) 2022-07-21
CN107580596A (zh) 2018-01-12
ES2753777T3 (es) 2020-04-14
PH12017502009A1 (en) 2018-03-26
MX2017014033A (es) 2018-03-01
WO2016180695A1 (en) 2016-11-17
HRP20191942T1 (hr) 2020-01-10
JP2018515509A (ja) 2018-06-14
TWI768467B (zh) 2022-06-21
RU2017142577A3 (enExample) 2019-10-31
IL280769B2 (en) 2023-07-01
SG10202108841YA (en) 2021-09-29
BR112017023959A2 (pt) 2018-07-17
IL254947A0 (en) 2017-12-31
HUE045906T2 (hu) 2020-01-28
HK1247925A1 (zh) 2018-10-05
BR112017023959B1 (pt) 2023-05-02
CN107580596B (zh) 2020-07-14
KR102690131B1 (ko) 2024-07-31
RU2745269C2 (ru) 2021-03-22
TW202108584A (zh) 2021-03-01
US10399983B2 (en) 2019-09-03
NZ775222A (en) 2024-09-27
CA2982704A1 (en) 2016-11-17
US20160326177A1 (en) 2016-11-10
US9708325B2 (en) 2017-07-18
AU2020256348B2 (en) 2022-06-16
LT3294740T (lt) 2019-11-25
US11242345B2 (en) 2022-02-08
CA2982704C (en) 2023-10-24
IL280769B1 (en) 2023-03-01
IL254947B (en) 2021-02-28
NZ735648A (en) 2023-06-30
TW201716410A (zh) 2017-05-16
PT3294740T (pt) 2019-10-29
UA120450C2 (uk) 2019-12-10

Similar Documents

Publication Publication Date Title
DK3294740T3 (da) Hidtil ukendte sulfonimidoylpurinonforbindelser og derivater til behandling og profylakse af virusinfektion
DK3504210T3 (da) 7-substituerede sulfonimidoylpurinonforbindelser til behandling og forebyggelse af virusinfektion
DK3349758T3 (da) Fremgangsmåder til behandling af arenaviridae-virusinfektioner
FI3684377T3 (fi) Menetelmiä hepatiitti b -infektion hoitamiseksi
LT3347352T (lt) Terapiniai junginiai, naudotini živ viruso infekcijos profilaktikai arba terapiniam gydymui
DK3302709T3 (da) Fremgangsmåder og sammensætninger til rna-guidet behandling af hiv-infektion
IL245436A0 (en) New dihydroquinolizinones for the treatment and prevention of hepatitis b virus infection
DK3521282T3 (da) Quinazolinderivater anvendt til behandling af hiv
HRP20190352T1 (hr) Novi 6-kondenzirani heteroarildihidropirimidini za liječenje i profilaksu infekcije virusom hepatitisa b
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3277270T3 (da) Sammensætninger og fremgangsmåder til behandling af anæmi
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
DK3081263T3 (da) Sammensætninger og redskaber til behandling af glaukom
DK3436074T3 (da) Thiazolidforbindelser til behandling af virale infektioner
DK3331879T3 (da) Benzazolforbindelser og fremgangsmåder til fremstilling og anvendelse af forbindelserne
DK3307267T3 (da) Behandling af multipel sklerose
DK3522873T3 (da) Sammensætninger og fremgangsmåder til behandlingen af xerostomi
DK3200748T3 (da) Sammensætninger og fremgangsmåder til behandling og profylakse af infektioner på operationssted
DK3137078T3 (da) Behandling af hepatitis delta-virusinfektion
DK3256466T3 (da) 1-heterocyclyl-isochromanylforbindelser og analoger til behandling af cns-forstyrrelser
DK3370723T3 (da) Behandling af hepatitis delta-virusinfektion
DK3386507T3 (da) Metoder og sammensætninger til behandling af mavesår
DK3471732T3 (da) Liposomer til behandling af virusinfektioner
DK3253406T5 (da) Sammensætninger til behandling af granulomatose med polyangiitis
DK3638370T3 (da) Behandling af migræne med acetyl-leucin